


STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN	LITRONESIB
PRONUNCIATION	lit ron nes' ib
THERAPEUTIC CLAIM	Antineoplastic

CHEMICAL NAMES

1. Propanamide, *N*-[4-(2,2-dimethyl-1-oxopropyl)-5-[[[2-(ethylamino)ethyl]sulfonyl]amino]methyl]-4,5-dihydro-5-phenyl-1,3,4-thiadiazol-2-yl]-2,2-dimethyl-, (-)-
2. (-)-*N*-{4-(2,2-dimethylpropanoyl)-5-[(2-(ethylamino)ethyl)sulfonyl]amino)methyl}-5-phenyl-4,5-dihydro-1,3,4-thiadiazol-2-yl}-2,2-dimethylpropanamide
3. (*R*)-*N*-{4-(2,2-dimethyl-propionyl)-5-[(2-ethylamino-ethanesulfonylamino)-methyl]-5-phenyl-4,5-dihydro-[1,3,4]thiadiazol-2-yl)-2,2-dimethylpropanamide

STRUCTURAL FORMULA



MOLECULAR FORMULA	C <sub>23</sub> H <sub>37</sub> N <sub>5</sub> O <sub>4</sub> S <sub>2</sub>
MOLECULAR WEIGHT	511.7
TRADEMARK	None as yet
MANUFACTURER	Eli Lilly and Company
CODE DESIGNATION	LY2523355; KF89617
<u>CAS</u> REGISTRY NUMBER	910634-41-2